{
    "nctId": "NCT03919253",
    "briefTitle": "Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study",
    "officialTitle": "Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study",
    "overallStatus": "UNKNOWN",
    "conditions": "HER2-positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "Progress-free survival(PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 1. Age: 18-70 years old\uff0cfemale; 2. Pathologically confirmed HER2-positive invasive breast cancer by local laboratory with the following requirements: HER2 overexpressed or amplified (immunohistochemistry of 3+ or HER2 gene amplification by in situ hybridization) 3. Imaging examination confirmed recurrent/metastatic breast cancer\uff1b 4. Patients must have previous treatment with trastuzumab more than 9 weeks; 5. Untreated for metastatic/metastatic disease (except for endocrinotherapy); 6. Patients with at least one measurable lesions by RECIST version 1.1\uff1b 7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2\uff1b 8. Life expectancy greater than or equal to 3 months; 9. Participants must have normal organ and marrow function as described below\uff1a Absolute neutrophil count\u22651.5\u00d7109/L; Platelets\u226590\u00d7109/L; Hemoglobin \u226590g/L\uff1b Total bilirubin \u2264 1.5 X institutional upper limit of normal (ULN)\uff1b ALT and AST\u22642\\*ULN, but \u22645\\*ULN with liver metastases; BUN and Cr\u22641.5\u00d7ULN or creatinine clearance \u226550ml/min Left ventricular ejection fraction (LVEF) \u2265 50% 10. Doctors believe that treatment can bring benefits to patients\uff1b 11. Participants were willing to join in this study, and written informed consent.\n\nExclusion Criteria:\n\n* 1. A variety of factors influencing oral drugs (after resection of the gastrointestinal, unable to swallow, Chronic diarrhea, intestinal obstruction); 2. Patients with other malignant tumors within 5 years (except for skin basal cell carcinoma and cervical carcinoma in situ); 3. History of psychiatric drugs abuse or patients with mental disorders; 4. Pregnant or lactating women; 5. Less than 4 weeks from the last clinical trial 6. The researchers think inappropriate.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}